Doc Code: TRACK1.REQ
`Document Description: TrackOne Request
`
`PTO/AlA/424 (04-14)
`
`CERTIFICATION AND REQUEST FOR PRIORITIZED EXAMINATION
`
`UNDER 37 CFR 1.102(e) (Page 1 of 1)
`
`Neridronic Acid for Treating Complex Regional Pain Syndrome
`
`APPLICANT HEREBY CERTIFIES THE FOLLOWING AND REQUESTS PRIORITIZED EXAMINATION FOR
`THE ABOVE-IDENTIFIED APPLICATION.
`
`
`
`1. The processing fee set forth in 37 CFR 1.17(i)(1) and the prioritized examination fee set forth in
`37 CFR 1.17(c) have been filed with the request. The publication fee requirement is met
`because that fee, set forth in 37 CFR 1.18(d), is currently $0. The basic filing fee, search fee,
`and examination fee are filed with the request or have been already been paid.
`I understand
`that any required excess claims fees or application size fee must be paid for the application.
`
`I understand that the application may not contain, or be amended to contain, more than four
`independent claims, more than thirty total claims, or any multiple dependent claims, and that
`any request for an extension of time will cause an outstanding Track I request to be dismissed.
`
`3. The applicable box is checked below:
`
`Ori
`
`inal Ao olication Track One - Prioritized Examination under ~
`
`i.
`
`(a) The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a).
`This certification and request is being filed with the utility application via EFS—Web.
`___OR___
`
`(b) The application is an original nonprovisional plant application filed under 35 U.S.C. 111(a).
`This certification and request is being filed with the plant application in paper.
`
`ii. An executed inventor’s oath or declaration under 37 CFR 1.63 or 37 CFR 1.64 for each
`
`inventor, g the application data sheet meeting the conditions specified in 37 CFR 1.53(f)(3)(i) is
`filed with the application.
`
`Re uest for Continued Examination - Prioritized Examination under
`
`.
`
`'
`
`A request for continued examination has been filed with, or prior to, this form.
`If the application is a utility application, this certification and request is being filed via EFS-Web.
`The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a), or is
`a national stage entry under 35 U.S.C. 371.
`. This certification and request is being filed prior to the mailing of a first Office action responsive
`to the request for continued examination.
`No prior request for continued examination has been granted prioritized examination status
`under 37 CFR 1.102(e)(2).
`
`
`3,9na,,,,e /Yueien Zhou/
`Date2017.1 1 -21
`
`Name
`(Print/Typed)
`
`Yuefen ZhOU
`
`Practitioner
`Registration Number
`
`73398
`
`This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications.
`Note:
`Submit multile forms if more than one sinature is re-uired. *
`
`*Total of
`
`1
`
`forms are submitted.
`
`Griin. Exh. 1037
`
`PGR for U.S. Patent No. 10,052,338
`
`1
`
`Grün. Exh. 1037
`PGR for U.S. Patent No. 10,052,338
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your
`submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of
`the Act, please be advised that: (1) the general authority forthe collection ofthis information is 35 U.S.C. 2(b)(2); (2)
`furnishing ofthe information solicited is voluntary; and (3) the principal purpose for which the information is used by the
`US. Patent and Trademark Office is to process and/or examine your submission related to a patent application or
`patent.
`If you do not furnish the requested information, the US Patent and Trademark Office may not be able to
`process and/or examine your submission, which may result in termination of proceedings or abandonment ofthe
`application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1. The information on this form will be treated confidentially to the extent allowed underthe Freedom of
`Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may
`be disclosed to the Department ofJustice to determine whether disclosure ofthese records is required by the
`Freedom of Information Act.
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
`to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of
`settlement negotiations.
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance from
`the Member with respect to the subject matter ofthe record.
`A record in this system of records may be disclosed, as a routine use, to a contractor ofthe Agency having
`need forthe information in orderto perform a contract. Recipients of information shall be required to comply
`with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`A record related to an International Application filed underthe Patent Cooperation Treaty in this system of
`records may be disclosed, as a routine use, to the International Bureau ofthe World Intellectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes
`of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C.
`218(c)).
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General
`Services, or his/her designee, during an inspection of records conducted by GSA as part ofthat agency’s
`responsibility to recommend improvements in records management practices and programs, under authority of
`44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing
`inspection of records forthis purpose, and any other relevant (i.e., GSA or Commerce) directive. Such
`disclosure shall not be used to make determinations about individuals.
`A record from this system of records may be disclosed, as a routine use, to the public afler either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance ofa patent pursuant to 35 U.S.C. 151. Further, a
`record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public ifthe record
`was filed in an application which became abandoned or in which the proceedings were terminated and which
`application is referenced by either a published application, an application open to public inspection or an issued
`patent.
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
`
`2
`
`

`

`F’TOJAiA/c-t (06-12)
`Approved far use through Qilfliifin‘iu, 0MB 0651-0032
`
`
`US. i’atentend Trademark Git
`i. US [EPA
`HEN“! OF COMMERCE
`
`““2.“
`xxmmwn
`wfiwwm‘mxfixxxxx
`\\\\\V~\\\\\
`Undertne gammai‘k Reduniton Act of 3995, m:- psrssns are required ts respond to a coiiectish sf irir‘orriiaficn L:
`sss it disptays a valid OMB cantroi numsar.
`
`EECLARATEQN {3? CFR 133} FQR UTiLiTY QR EESiGi‘é APPLECATEGN US’EENQ AN
`APPLiCflTiQN {BATA SHEET (3? QFR 133}
`~ «. ‘. ..... “
` “m-s-bbKKRRR \‘<~'«-~ .?h“.->R\W\s«~« ‘“ .
`
`
`
`‘i’itis cf
`
`iiwentien ----
`
`NERiDRQNiC ACiD FQR TREATENG COMPLEX REGEGNAL PAEN SYNQRQME
`
`, ,
`
`\‘wmmwnwmmwmw\\w««
`
`1 As the heinw named inventer‘ i hereby declare that:
`
`This decisrstmn § The attached appiicstion= at
`is directed to:
`1‘------
`
`L‘
`
`Unfled States appiiCEfiifi)n Cu" PCi inteET]afiQn35 a(3;)iiCafiiD{i number ‘Wmhmm-m“N““N‘w
`
`flied 03} mm
`
`: The shaveuidsntified application was; made er sutherized it: he made by me
`
`
`
`believe that i am the (triginai inventer er an original ioirt‘i inventer eta ciaimeci invantian in the applicatian.
`
`g
`
`i hereby acknowledge that any wiiifui faise statement mass in this declaraticn is punishable: under 18 {3.3.8. 1001
`by fine or imprisonment of not mere than this (5) years, 9r both.
`
`WARNENQ:
`
`Petitioner'iapeiicant is cautioned it: avaici submitting personal infatuation in decuments iiied in a patent appiicatiun that may
`centrihute: to identity theft. Permits! information such as; saciai security numbers bank account numbers, or credit card numbers ‘
`: (ether than a check (tr credit card authorization farm PTO-2038 submitted far Qaymeht purposes) is never required by the USPTO ‘
`its) support a fietiticn at" as applicatinh.
`if this type at personal infm‘matien is inciuded in dscuments sutamittsci t0 the USP'i'Q
`setttimtsrsi’appiicaitts‘ should mssicier ¥€§€Cfig
`sash miseries infarmatien from the dc-mmsnts «We sass;
`‘
`ing them to the
`
`USPTG. Petitionsfismiicsiit is ss‘isises tits: the tasters:
`:3 satent application is avaiiainis: it! the misfit: after piibilcstisn cf the
`appiicatisn (uriiess a non subiicatien request in cemplisnse with 37' CFR i.213is) is made: in the'applicatiefi) or issuance sf 3
`
`gastsnt; Fltfihfimaffl,‘ tins 931'.
`stars is: etissntishstistiiitissiim mg}: gigs fig‘gvgaguifi'fifig es
`,
`'ishg gpgiifaaiém‘. is
`
`
`
`
`
`'
`‘
`visit in a smashed amp-asses tit-sit issuss? gssi‘v“ game 3? CFR “ its assets sat? sis
`“3rd authsrizatisnisms
`
`
`
`sass stsiimitiesti is: §33¥fitafii ys‘rpssessamtmt re .
`‘
`'
`‘
`:
`'
`.. > and tissrstsi‘s'sts not pshiétsg s‘ssiis .s
`
`
`
`
`
`LEGAL NAME OF iNVE-ENTGR
`
`inventor;
`
`Herrist stutesu
`
`iii artist Tshuteau!
`Signature. ‘
`
`We (Optisitai) .
`
`Note: An ahpticstion data sheet (PTOISB/M or equivalent), inciuding naming the entire lhventive entity, must accempany this farm at“ must have:
`_ been previeusly fiies‘. Use an esc'diiimai PTOIAWM form for each additicnai inventor
` This coiiection efi i
`
`required tr; obtain Gi’ retain a benefit by the public which ES to fits (and
`inn is required by 35 U 5.6 ‘ 5 and 37’ CFR 1.63,. The information
`by the: USPTQ tr: pmc‘
`s} an applicatiarr Cuni’ideriti
`‘ty is gwamsd by 35 L) SID. 122 amt (4.7 CPR ‘ixli and 1‘14. This caiierfiion is estimated tc take 1 minute to
`
`
`
`campieie, including gathering pteparing. and summit’
`.g til-3 campieted applicatian farm tr:- the USFTO.
`"as wiii van: depend 5,: upon the individuai case; Any
`comments an the amount sftime yc-u require to compiata this form andicr suggestrons fur resuming ih's burden, should as sent to the Chief infermatinh Cfiicer. US.
`Patent and Tiademark Cities, US. Bepsrtmem sf Cortirtisrce. PC). Bax 1450. Alexandn’a, VA 22313-1450. DO NOT SEND FEES GR COMPLETED FQRMS TO
`THIS ADDRESS. SENEB TO: Cummissierier fer Patents, RE). Sex 165:), Aiexsndria, VA 22313445fi.
`
`
`
`3
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`US Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`-
`
`-
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`
`Title of Invention
`
`Neridronic Acid for Treating Complex Regional Pain Syndrome
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.78.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2:
`
`
`I:I Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`
`
`Middle Name
`
`
`Family Name
`
`Non US Residency
`
`Active US Military Service
`
`
`
`Mailing Address of Inventor:
`
`
`
`Address 1
`AddressZ
`
`I5 Broadway, 9th Floor
`
`I_
`
`generated within this form by selecting the Add button.
`
`v
`| statervrovince
`
`Countryi
`Postal Code
`
`All
`
`Inventors Must Be Listed — Additional
`
`Inventor Information blocks may be
`
`
`Correspondence Information:
`
`Enter either Customer Number or complete the Correspondence Information section below.
`
`For further information see 37 CFR 1.33(a).
`
`
`
`D An Address is being provided for the correspondence Information of this application.
`Customer Number
`TI°149
`Email Address
`IDocket@mabr.com
`
`Application Information:
`
`
`Title of the Invention
`
`eridronic Acid for Treating Complex Regional Pain Syndrome
`
`Attorney Docket Number
`
`‘ 3226.10005US49
`
`Small Entity Status Claimed
`
`
`
`
`
`SubjectMauer —:
`Total Number of Drawing Sheets (it any)
`Suggested Figure for Publication (if any)
`
`EFS Web 2.2.12
`
`4
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`Attorney Docket Number
`A3226.10005US49
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Neridronic Acid for Treating Complex Regional Pain Syndrome
`
`Title of Invention
`
`Filing By Reference:
`
`Only complete this section when filing an application by reference under 35 U.S.C. 1 11(c) and 37 CFR1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`
`provided in the appropriate 5ection(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").
`
`For the purposes of a filing date under 37 CFR1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).
`i
`
`Application number of the previously
`filed application
`
`Filing date (YYYY—MM-DD)
`
`Intellectual Property Authority or Country
`
`
`
`fififi
`
`
`Publication Information:
`
`D Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`Request Not to Publish. I hereby request that the attached application not be published under
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`
`publication at eighteen months after filing.
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below.
`If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`US Patent Practitioner 0 Limited Recognition (37 CFR 11.9) Customer Number
`
`0 Customer Number
`I-7149
`
`Please Select One:
`
`
`Domestic Benefithational Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate
`National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes
`the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the "Application Number” field blank.
`
`Application Number
`
`Continuity Type
`
`Remove
`
`
`
`
`
`
`Filing or 371(c) Date
`
`
` Prior Application Number
`
`(YYYY-MM-DD)
`
`' 017—09—13
`
`
`
`
`
`
`
`
`
`I—I_I
`
`EFS Web 2.2.12
`
`5
`
`

`

`
`
`Prior Application Status_l
`Remove
`
`'
`'
`'
`Issue Date
`"
`
`Application
`Continuity Type
`Prior Application
`Filing Date
`
`
`
`Number
`Number
`(—YYYYMM——DD)
`Patent Number
`(YYYY-MM—DD)
`
`
`I151703891I_“151360886
`I' 01611—23
`-770457
`017—09—26
`
`PriorApplication Status_I
`Remove
`
`
`
`
`
`Prior Application
`Filing Date
`Issue Date
`Application
`.
`.
`
`
`
`Number
`Continuity Type
`Number
`(YYYY-MM-DD)
`Patent Number
`(YYYY-MM-DD)
`
`l2016—07—22 9623038 l2017—04—18
`
`15/360886
`
`ontinuationIn part of I 15/217773
`
`
`
`
`Remove
`
`
`
`Prior Application Status I—l
`
`
`
`
`Prior Application
`Filing Date
`Issue Date
`Application
`.
`.
`
`
`
`(YYYY-MM-DD)
`Pater“ Number
`(YYYY—MM—DD)
`Number
`commu'w Type
`Number
`
`
`15/217773
`ontinuation of
`I 14/967224
`r 015—12—11
`v
`I' 016-08-09
`
`Remove
`
`
`
`'
`'
`'
`"
`Issue Date
`
`
`Prior Application
`Filing Date
`
`
`Number
`(YYYY—MM——DD)
`Patent Number
`(YYYY-MM—DD)
`
`I141967224' I_fil141604524
`I'01501—23
`-211257
`015—12—15
`
`
`
`
`
`Filing or 371(c) Date
`
`
` Prior Application Number
`(YYYY-MM-DD)
`
`
`I'(Il14—11—O7
`I 141536526
`
`
`Remove
`
`
`Prior Application
`Filing Date
`Issue Date
`.
`.
`
`
`Number
`(YYYY—MM—DD)
`Patent Number
`(YYYY—MM—DD)
`Continuity Type
`
`
`
`
`0140729
`1115—04—14
`I ontinuation in part of “141446184
`
`
`
`
`
`
`Filing Date
`Prior Application
`
`
`(YYYY-MM-DD)
`Patent Number
`Number
`
`
`V 014—05—28
`I' 014—09—16
`H 141288716
`
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`
`
`
` (YYYY-MM-DD)
`
`
`
`
`
`Issue Date
`
`PTO/AlA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`Attorney Docket Number
`A3226.10005US49
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`
`Title of Invention
`
`Neridronic Acid for Treating Complex Regional Pain Syndrome
`
`
`
`
`
`Application
`Number
`
`Continuity Type
`
`
`
`Application Number
`
`Continuity Type
`
`I 41604524
`
`I ontinuation in part of
`
`
`
`
`
`
`
`
`
`
`Application
`
`
`
`I141536526
`
`Application
`Number
`
`141446184
`
`
`.
`.
`Continuity Type
`Division of
`
`Application Number
`
`
`
`I laims benefit of provisional
`
`Continuity Type
`
`Prior Application Number
`
`
`
`
`
`I 611933608
`014—01-30
`I 41288716
`
`
`
`
`
`
`
`.
`.
`A lication
`Prior A lication
`Filin Date
`ISSUE Date
`
`
`
`pp (YYYY-MM-DD) Continuity Type pp (YYYYSJMM-DD) Patent Number
`
`
`
`
`
`
`
`
`' 014—05—15
`I' 015—05-19
`
`
`PriorApplication Status_I
`Remove
`
`
`
`
`
`
`
`
`Application
`
`.
`
`.
`
`Prior Application
`
`Filing Date
`
`I14/279229
`
`I ontinuation of
`
`HIM/063979
`
`Iro13—1o—25
`
`EFS Web 2.2.12
`
`
`
`
`
`,: 802658
`
`
`
`Issue Date
`
`014—08-12
`
`
`
`6
`
`

`

`PTO/AlA11 4 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`Attorney Docket Number A3226.10005US49
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`
`Title of Invention
`
`Neridronic Acid for Treating Complex Regional Pain Syndrome
`
`Application Number
`
`Continuity Type
`
`I 41063979
`
`I ontinuation in part of
`
`I 13/894274
`
`Remove
`
`
`
`
`Filing or 371(c) Date
`
`
`
`Prior Application Number
`
`(YYYY-MM-DD)
`
`
`'013—05—14
`
`
`Filing or 371(c) Date
`(yvyy-M|\/|-DD)
`
`Prior Application Number
`
`Application Number
`
`Continuity Type
`
`Application Number
`
`Continuity Type
`
`
`
`
`
`
`
`
`
`
`
`I 611803721
`I laims benefit of provisional
`I 31894274
`'013—03—20
`
`
`
`
`Prior Application Status Im:
`Remove
`
`
`
`Filing or 371(c) Date
`
`
`
`
` Prior Application Number
`(YYYY-MM-DD)
`
`I013—0221
`I 611767647
`I laims beneft of prOVISIonal
`I 31894274
`
`
`_emove
`Prior Application Status Im:
`Fil-in_gor 371(c) Date
`
`
`
`Prior Application Number
`(YYYY-MM-DD)
`
`
`' 01 13—02—21
`I 611767676
`
`
`Remove
`
`
`
`
`Filing or 371(c) Date
`
`
`
` Prior Application Number
`(YYYY-MM-DD)
`
`
`
`'013—02—14
`
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Application Number
`
`Continuity Type
`
`I 31894274
`
`I laims benefitof provisional
`
`Application Number
`
`Continuity Type
`
`I 31894274
`
`I laims benefitof provisional
`
`Application Number
`
`Continuity Type
`
`I 31894274
`
`I laims benefit of provisional
`
`Application Number
`
`Continuity Type
`
`I 31894274
`
`I laims benefit of provisional
`
`Application Number
`
`Continuity Type
`
`I 61/764563
`
`Prior Application Number
`
`
`
`
`
`I 611762225
`'013—02—07
`
`
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`I 61/655541
`'012—06—05
`
`
`
`
`
`
`
`
`
`
` Prior Application Number
`
`
`
`Prior Application Number
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`
`I012—06_—05
`I 611655527
`I laimsbeneftofprovisional
`'—31894274
`Fil-in-gor 371(c) Date
`
`
`(YYYY-MM-DD)
`
`'012—06—01
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`I 31894274
`
`EFS Web 2.2.12
`
`I laims benefit of provisional
`
`I 611654383
`
`7
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`Attorney Docket Number A3226.10005US49
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`
`Title of Invention
`
`Neridronic Acid for Treating Complex Regional Pain Syndrome
`
`Remove
`
`
`
`
`Filing or 371(c) Date
`
`
`
`Prior Application Number
`
`(YYYY-MM-DD)
`
`
`'012—06—01
`
`
`Filing or 371(c) Date
`(yvyy-M|\/|-DD)
`
`Prior Application Number
`
`I 61/654292
`
`Application Number
`
`Continuity Type
`
`I 3/894274
`
`I laims benefit of provisional
`
`Application Number
`
`Continuity Type
`
`Application Number
`
`Continuity Type
`
`
`
`
`
`
`
`
`
`
`
`I 61/647478
`I laims benefit of provisional
`I 31894274
`'012—05—15
`
`
`
`
`Prior Application Status Im:
`Remove
`
`
`
`Filing or 371(c) Date
`
`
`
`
` Prior Application Number
`(YYYY-MM-DD)
`
`I012—0514
`I 61/646538
`I laims beneft of prOVISIonal
`I 31894274
`
`
`_emove
`
`_riorApplication Status—Iml
`Fil-in_gor 371(c) Date
`
`
`
`Prior Application Number
`(YYYY-MM-DD)
`
`
`' 01 5—05—27
`I PCT/US2015I032739
`
`
`Remove
`
`
`
`
`Filing or 371(c) Date
`
`
`
` Prior Application Number
`(YYYY-MM-DD)
`
`
`
`014—08—08
`
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`
`
`
`
`
`
`
`Application Number
`
`Continuity Type
`
`I 5/360886
`
`I ontinuationIn part of
`
`Application Number
`
`Continuity Type
`
`I - CTIU820151032739 _I PCT/US2014/050427
`
`
`
`
`
`
`
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`I - CTIU820141050427 _I 14/279241
`
`1114—05—15
`
`
`Issue Date
`Filing Date
`Prior Application
`.
`.
`Application
`
`Continuity Type
`(YYYY—MM—DD)
`(YYYY-MM—DD)
`Patent Number
`
`0'1—707—11
`'01-711-21
`
`
`
`
`Application Number
`
`Continuity Type
`
`
`
`
`Fil-in_gor 371(c) Date
`
`Prior Application Number
`(YYYY-MM-DD)
`
`
`
`201 6-08-22
`
`I 62/378140
`I laims benefit of provisional
`I 51647140
`
`
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
` Add
`
`
`by selecting the Add button.
`
`
`
`
`
`Foreign Priority Information:
`EFS Web 2.2.12
`
`8
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`_
`_
`Application Data Sheet 37 CFR 1.76
`
`A3226.10005US49
`Attorney Docket Number
`
`
`Application Number
`
`Title of Invention
`
`Neridronic Acid for Treating Complex Regional Pain Syndrome
`
`Add button.
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.5_5. When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (PDX)l the information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1)_
`
`Remove
`
`Application Number
`
`I
`
`Access Codei (if applicable)
`
`
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`
`
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`
`Applications
`
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`D 16, 2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`16, 2013, will be examined under the first inventor to file provisions of the AIA.
`
`EFS Web 2.2.12
`
`9
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`Attorney Docket Number A3226.10005US49
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Neridronic Acid for Treating Complex Regional Pain Syndrome
`
`Title of Invention
`
`Authorization or Opt-Out of Authorization to Permit Access:
`
`When this Application Data Sheet is properly signed and filed with the application, applicant has provided written
`authority to permit a participating foreign intellectual property (IP) office access to the instant application—as-filed (see
`paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant
`application (see paragraph B in subsection 1 below).
`
`Should applicant choose not to provide an authorization identified in subsection 1 below, applicant must opt-out of the
`authorization by checking the corresponding box A or B or both in subsection 2 below.
`
`NOTE: This section of the Application Data Sheet is ONLY reviewed and processed with the INITIAL filing of an
`application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind
`authorization for access by a foreign lP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.
`
`
`
`1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)
`
`
`A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the
`undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office
`(JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People’s Republic of
`China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office
`participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign
`application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed
`and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the
`instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)
`(1)-
`
`
`B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt—out of authorization) is checked,
`the undersigned hereby grants the USPTO authority to provide the EPO access to the bibliographic data and search
`results from the instant patent application when a European patent application claiming priority to the instant patent
`application is filed. See 37 CFR 1.14(h)(2).
`
`The applicant is reminded that the EPO’s Rule 141(1) EPC (European Patent Convention) requires applicants to submit a
`copy of search results from the instant application without delay in a European patent application that claims priority to
`the instant application.
`
`2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Applicant DOES NOT authorize the USPTO to permit a participating foreign IP office access to the instant
`D application-as—filed.
`If this box is checked, the USPTO will not be providing a participating foreign IP office with
`any documents and information identified in subsection 1A above.
`
`|:|
`
`B. Applicant DOES NOT authorize the USPTO to transmit to the EPO any search results from the instant patent
`application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant
`application.
`NOTE: Once the application has published or is othenNise publicly available, the USPTO may provide access to the
`application in accordance with 37 CFR 1.14.
`
`EFS Web 2.2.12
`
`10
`
`10
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`Attorney Docket Number
`A3226.10005US49
`
`Neridronic Acid for Treating Complex Regional Pain Syndrome
`
`Title of Invention
`
`Applicant Information:
`
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`
`1
`Applicant
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`Legal Representative under 35 U.S.C. 117
`
`Joint Inventor
`
`Person to whom the inventor is obligated to assign.
`
`Person who shows sufficient proprietary interest
`
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`
`
`
`
`
`Name of the Deceased or Legally lncapacitated Inventor:
`
`If the Applicant is an Organization check here.
`
`IX
`
`Mailing Address Information For Applicant:
`
`Address 1-30 FIFTH AVENUE, SUITE 2000
`
`AddressZ
`
`
`
`Email Address
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`Assignee Information including Non-Applicant Assignee Information:
`
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title
`37 of CFR to have an assignment recorded by the Office.
`
`
`EFS Web 2.2.12
`
`11
`
`11
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Attorney Docket Number A3226.10005US49
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`
`Title of Invention
`
`Neridronic Acid for Treating Complex Regional Pain Syndrome
`
`
`
`Assignee 1
`Complete this section if assignee information, including non—applicant assignee information, is desired to be included on the patent
`application publication. An assignee—applicant identified in the "Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee—applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`Remove
`
`
`
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`|:|
`
`Given Name
`
`Middle Name
`
`Family Name
`
`
`
`selecting the Add button.
`
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`
`
`Phone Number
`
`Fax Number
`
`Email Addre